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Glioblastoma multiforme (GBM) is the most aggres-
sive form of brain cancer with marginal life expec-
tancy. Based on the assumption that GBM cells
gain functions not necessarily involved in the
cancerous process, patient-derived glioblastoma
cells (GCs) were screened to identify cellular pro-
cesses amenable for development of targeted treat-
ments. The quinine-derivative NSC13316 reliably and
selectively compromised viability. Synthetic chemi-
cal expansion reveals delicate structure-activity rela-
tionship and analogs with increased potency, termed
Vacquinols. Vacquinols stimulate death by mem-
brane ruffling, cell rounding, massivemacropinocytic
vacuole accumulation, ATP depletion, and cyto-
plasmic membrane rupture of GCs. The MAP kinase
MKK4, identified by a shRNA screen, represents a
critical signaling node. Vacquinol-1 displays excel-
lent in vivo pharmacokinetics and brain exposure, at-
tenuates disease progression, and prolongs survival
in a GBM animal model. These results identify a
vulnerability tomassive vacuolization that can be tar-
geted by small molecules and point to the possible
exploitation of this process in the design of anti-
cancer therapies.INTRODUCTION
Tumor development involvesmutations that can begain-of-func-
tion mutations in proto-oncogenes or loss-of-function mutations
in tumor suppressor genes that lead to fundamental changes inthe biology of the cell, resulting in cancer. Genomic studies of
hundreds of glioblastoma multiforme (GBM) samples have led
to a comprehensive insight into the genomic landscape of
GBM, revealing both gain- and loss-of-function in core signaling
pathways commonly activated, including the receptor tyrosine
kinase (RTK/RAS) oncogenic pathway with alterations in EGFR/
PDGFRA/PI3K/PTEN/NF1/RAS, the p53 pathway with changes
in TP53/MDM2/MDM4/p14ARF, and finally, the cell-cycle regu-
latory pathway with alterations in RB1/CDK4/p16INK4A/
CDKN2B, with most GBM tumors having genetic alteration in
all three pathways (Chen et al., 2012b; Furnari et al., 2007; Par-
sons et al., 2008; Brennan et al., 2009, 2013; Verhaak et al.,
2010; Cancer Genome Atlas Research Network, 2008). The
consequence is a fueling of cell proliferation and enhanced sur-
vival and invasion properties, while preventing tumor cells from
apoptosis and activation of cell-cycle checkpoints. Consistently,
malignant gliomas are among the most devastating human can-
cers (Louis et al., 2007). GBM is essentially incurable, even when
aggressive therapies based on surgical tumor resection and
concomitant chemotherapy and radiotherapy are implemented
(Stupp et al., 2005), and only 3%–5% of patients survive longer
than 3 years due to disease recurrence (Dolecek et al., 2012).
The small population of GBM cells with stem/progenitor cell
characteristics (Hemmati et al., 2003; Singh et al., 2003, 2004)
seed growth of new tumors (Gallo et al., 2013; Pollard et al.,
2009; Singh et al., 2003, 2004) and drivemalignancy, metastasis,
and tumor recurrence, promoting resistance against radiation-
based therapy (Bao et al., 2006) and chemotherapy (Bleau and
Holland, 2009; Chen et al., 2012b). These tumor-initiating cells
are believed to be relatively quiescent (Alcantara Llaguno et al.,
2009; Barami et al., 2009), which could contribute to disease
recurrence following current therapeutic strategies targeting
intracellular processes associated with cell division.
Unlike several other forms of cancer in which identification of
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neutralizing the function gained by the genetic alterations, the
complexity and diversity of glioblastoma genetics have pre-
vented a simple strategy for therapeutic targeting. New ap-
proaches focused on neutralizing abnormalities underlying
tumor development have only had limited success so far (Dent
et al., 2008; Polivka et al., 2012).We reasoned that gene products
causing glioma are part of signaling pathways that are involved in
diverse cellular functions. Therefore, gain- and loss-of-function
mutations would be predicted to lead to acquired functions
also in cellular properties not necessarily involved in cell transfor-
mation and proliferation. Hence, there should be unique cellular
properties of glioma that are low or absent in other cell types. If
identified, such features can be exploited for development of
conceptually new strategies of therapy. In an unbiased pheno-
typic screen using a diversity set of small molecules on glioblas-
toma cells (GCs), a biological process resulting in a robust loss of
viability and increased cytotoxicity was discovered. GCs are
vulnerable to an MKK4-dependent signaling inducing cata-
strophic vacuolization and cell death.
RESULTS
Induction of Rapid and Specific Cell Death of Glioma
Cells by a Small Molecule
In order to identify pathways vulnerable for targeted treatment of
GCs, a phenotypic screenwas performed to identify compounds
active on GCs without affecting embryonic stem cells or human
fibroblasts. GC cultures were independently generated from
two cases of GBM, according to Pollard et al. (2009) which
allows for adherent growth of cells with tumor-initiating and
stem-like properties. These cell lines, designated U3013MG
and U3047MG, were screened, rescreened, and confirmed us-
ing 1,364 compounds of the NIH diversity set II for phenotypic
changes observed following phalloidin staining (Figure 1A and
Figure S1A available online). 234 compounds showed effects
after 2 days with principal phenotypes observed designated as
tiny (T, dead or reduced cell size) or loose or fuse (LOF, senes-
cence-like morphology), respectively (Figures 1B–1D). Filter
screens against mouse embryonic stem cells (mESCs) and
human fibroblasts reduced the initial 234 compounds to 63
with effects selective for GCs (Figures 1A and S1B). The com-
pounds were confirmed active on U3013MG and U3047MG
GCs, as well as on seven other patient-derived GC cultures
that were established (U3024MG, U3017MG, U3031MG,
U3037MG, U3086MG, U3054MG, and U3065MG; Figures 1A
and S1E). The 63 compounds (Table S1) were examined in a re-
covery assay (Figures S1C andS1D) by quantification of cytotox-
icity, apoptosis, and cell viability (Figure S2A) in U3013MG GCs
and human fibroblast cells, as well as cell-cycle analysis by flow
cytometry (Figure S2B). In the recovery assay, 2 days with com-
pound were followed 2 more days without compound. Only 12
compounds had an irreversible effect at the same concentration
that caused the acute effects (Figures S1C and S1D). Quantifica-
tion of cell viability (ATP) and cytotoxicity (CytoTox-Glo) of the 63
compounds identified partly the same hit compounds (i.e., E5,
E10, and A7) as most efficacious with limited effects on fibro-
blasts (Figure S2A). Based on these analyses and in silico
absorption, distribution, metabolism, and excretion (ADME) pre-314 Cell 157, 313–328, April 10, 2014 ª2014 Elsevier Inc.diction (Figures S3A–S3J), a refined list of 17 hits (Table S2) was
pursued using several parameters, including cell-type-selective
in vitro and in vivo efficacy, Ca2+ imaging, and toxicity tests. A
hanging drop-based mixed culture procedure was developed
for assaying selectivity (Figures S4A and S4B). U3013MG GCs
and fibroblasts labeled with cell tracker red or green fluorescent
dye, respectively, in cocultures confirmed selectivity (Fig-
ure S4B). Only one compound (D1) inducedCa2+ flux inGCs (Fig-
ures S4C–S4E). To measure toxicity, increasing concentrations
of the 17 hits administered to the water of 10 days postfertiliza-
tion (dpf) zebrafish embryos revealed that, whereas B6, B11, E5,
E9, C2, C7, and D12 did not affect zebrafish development,
embryos died, decayed, or displayed yolk edema in the pres-
ence of the remaining hits (Figure S5A). Cardiovascular toxicity
of ex vivo adult zebrafish hearts (Kitambi et al., 2012) was
observed for four hits (A2, A6, C9, and E9) whereas small or no
effects were found on the remaining compounds (Figure S5B).
In vivo efficacy was examined in a zebrafish GBM model that
was developed where 3,000 U3013MG GCs labeled with cell
tracker red were injected intracranially into the ventricle of 48–
52 hpf larvae. The 17 hits administered to the egg water at the
lowest effective in vitro cytotoxic concentration and monitoring
tumor development 10 days later revealed that B7, C2, and E5
markedly reduced tumor size, with E5 being most potent (Fig-
ure S5C). Based on these analyses, further studies were focused
on compound E5, which we name Vacquinol-1 due to its
quinoline-alcohol scaffold (Figure 1E). Vacquinol-1 displayed
high cytotoxicity (15 mM, 12 hr; Figure 1F), led to a complete
loss of viability as measured by ATP depletion (Figure 1G), and
selectively targeted GCs in mixed cocultures with human fibro-
blasts (Figures 1H and 1I). Vacquinol-1 did not affect mESCs, hu-
man fibroblasts, or osteosarcoma cells (Figures 1J–1O) but
rapidly reduced the proportion of GCs in S and G2/M cell-cycle
phases (7.5 mM, 12 hr; Figure 1P). Cell density had only minor
effects on viability in dose response assays (Figure 1Q). The me-
dian inhibition concentration of 50% (IC50) was 2.36 mM (3,000
cells/cm2, 24 hr, Figure 1R) as compared to 139 mM by temozo-
lomide (Figure 1S, 48 hr), a commonly used drug for treating gli-
oma. The IC50 of Vacquinol-1 remained largely similar at 2, 3, and
4 days of incubation (Figures 1T–1V). Mouse glia and neuron cul-
tures showed an IC50 of 15 and 29 mM, respectively (24 hr, Fig-
ures 1W and 1X), and fibroblasts showed an IC50 of 18.7 mM
and 23 mM (24 and 96 hr, respectively; Figures 1Y and 1Z). The
IC50 of fibroblasts was not affected by changing to GC culture
medium during Vacquinol-1 treatment (Figures S1F and S1G).
Furthermore, Vacquinol-1 was ineffective on bladder, prostate,
breast, and neuroblastoma cancer cell lines (Figure S1H).
Induction of a Catastrophic Unconventional Cell Death
Pathway by Vacquinol-1
Apoptosis is associated with a rapid loss of ATP. Vacquinol-1
administration (7.5 mM, 7 hr) led to a marked and significant
increase of dead cells analyzed by flow cytometry, similar to
staurosporin (1 mM, 7 hr; Figures 2A–2F). The apoptosis inhibitor
Q-VAD only modestly rescued cells from death at 3 and 7 hr
(Figure 2F). Active cleaved Caspase-3 was not increased
by Vacquinol-1 as compared to vehicle-treated cultures,
whereas doxorubicin (10 mM) markedly increased positive cells
Figure 1. Identification of GC Vulnerability to Vacquinol-1
(A) Schematic representation of the screening process and hit selection.
(B–D) GC phenotypes, normal phenotype, tiny phenotype, or loose of fuse phenotype (B, C, and D, respectively).
(E) Structure of identified hit Vacquinol-1.
(F) Cytotoxicity by Vacquinol-1 (15 mM) on GCs compared to DMSO and Staurosporin (10 mM).
(G) Viability (ATP) assay of Vacquinol-1 (15 mM, 2 days).
(H and I) Selective effects of Vacquinol-1 (15 mM) (I) as compared to DMSO (H) on GCs (red) in mixed culture assay with fibroblasts (green).
(J–O) Response of mESCs (J and K), human fibroblasts (L and M), and osteosarcoma cells (N and O) (DMSO: J, L, and N; Vacquinol-1 15 mM: K, M, and O).
(P) Cell-cycle analysis.
(Q–Z) Dose response of Vacquinol-1 in viability assay (ATP). Scale bars, 50 mm (B–D), 100 mm (H and I), and 100 mm (J–O).
Abbreviations: GC, glioblastoma cells; HFS, human fibroblast, mESC; mouse embryonic stem cells; TMZ, Temozolomide; mGlia, mouse glia cells; Vacq,
Vacquinol-1; Stau, staurosporin. Mean ± SD; t test, ***p < 0.001. See also Figures S1, S2, S3, S4, and S5.
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Figure 2. A Rapid Nonapoptotic Death by Vacquinol-1
(A–E) Flow-cytometry-based quantification of live and dead GC after 7 hr exposure (7.5 mM Vacquinol-1, 10 mM staurosporin).
(F) Quantification of live GCs after 3 hr or 7 hr of treatment.
(G–J) Active cleaved Caspase-3 (green) and phalloidin counterstaining (red) on GCs.
(K) Quantification of Caspase 3 and 7 activity.
(L–N) TMRE and ER tracker staining of GCs after 7 hr exposure to DMSOor 7.5 mMVacquinol-1 followed by quantification of TMRE intensity (N). Scale bars, 50 mm
(G–J, L, and M).
Abbreviations: a.u., arbitrary units; ns, not significant; RLUs, relative luminescence; Sta, Staurosporin; Vacq, Vacquinol-1. Mean ± SD; t test, **p < 0.01 to DMSO.
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(Figures 2G–2J). Caspase-3 and Caspase-7 enzymatic activity
was measured between 5 and 600 min after addition of
Vacquinol-1 at increasing concentrations (5–30 mM). Unlike
staurosporin, Vacquinol-1 had no effect on caspase activity at
any concentration or time point (Figure 2K). The accumulation
of tetramethylrhodamine ethyl ester (TMRE) in mitochondria
and the endoplasmic reticulum is driven by their membrane
potential. TMRE incorporation in mitochondria was largely unaf-
fected by Vacquinol-1 (7.5 mM, 7 hr; Figures 2L–2N). In ratiomet-
ric calcium imaging with ATP as positive control, cytosolic
calcium flux was not affected by Vacquinol-1 (Figures 3A, 3B,
3A0, and 3B0). These results show that Vacquinol-1-induced
GC death occurs by a nonapoptotic mechanism and does not
involve a disruption of active mitochondria.
Autophagy-associated cell death is the most widely studied
form of nonapoptotic cell death (Gozuacik and Kimchi, 2007).
LC3-II is conjugated to phosphatidylethanolamine on autopha-
gosomic membranes. Vacquinol-1 did not increase LC3-II immu-
noreactivity (Figures 3C and 3D). Scanning electron microscopy
on Vacquinol-1-treated GCs revealed a rapid rounding of cells
and appearance of membrane invaginations curved into crater-
like cups on the cell surface membrane (Figure 3F, arrowheads),
indicating an endocytic-like activity. Consistently, live-cell imag-
ing at high magnification revealed the formation of spherical pro-
trusions, blebs, appearingwithin seconds of exposing the cells to
Vacquinol-1 (MovieS1).With standardphase contrast optics, live
imaging revealedwithinminutes of Vacquinol-1 exposure (15 mM)
cell rounding and the formation ofmassivemembrane ruffles and
eventual death of cells by a rupture of the cytoplasmic mem-
brane, preceded by a marked contraction of the cytoplasmic
membrane followed by uncontrolled expansion resulting in its
rupture (Figure 3G and Movies S2 and S3). Live imaging with
Nomarski optics showed a rapid formation of intracellular vacu-
oles and membrane invaginations within 10 min of Vacquinol-1
(3.5 mM) with a dose-dependent increase of vacuole formation.
Vacuole size and numbers increased with time (Figure 3H and
Movie S3) and led to displacement of the cytoplasm with large
vacuoles and eventually cell rupture. These results confirm an in-
duction of endocytic-like activity by Vacquinol-1.
Using orthogonal (z stack projection) overlap of several bright-
field focal planes in a 3D image stack taken from a single-well im-
age field, large vacuoles of varying sizes were clearly observed
as lucent, a characteristic of vacuoles resulting frommacropino-
cytosis (Figure 4A). Another unique feature of macropinocytosis
is a large nonselective internalization of fluid trapped beneath
the projections of plasma membrane during membrane ruffling
(Mercer and Helenius, 2012; Swanson, 2008). Hence, rapid
incorporation of extracellular-phase fluid tracers is a hallmark
of macropinosomes. The tracer lucifer yellow (LY) in the medium
was taken up in most or all cells within 20 min (Figures 4B–4E;
7.5 mM Vacquinol-1) with an appearance within vacuoles (Fig-
ures 4F–4H). Internalization of LY was observed occasionally in
nonstimulated GCs but at a very low rate compared to Vacqui-
nol-1. Clathrin-independent endocytosis of the macropinocyto-
sis type is sensitive to the specific inhibitor of the vacuolar-type
H+-ATPase, Bafilomycin A1 (Baf-A) (Kaul et al., 2007; Overmeyer
et al., 2011). A short-term (1 hr) incubation of GCs with 100 nM
Baf-A had no effect by itself on uptake of LY but completelyabrogated Vacquinol-1-induced LY uptake (Figure 4I). Macropi-
nocytosis is also sensitive to perturbation of the activity of Dyna-
min by dynasore (Gold et al., 2010) and actin by Cytochalasin D
(Grimmer et al., 2002), which both completely prevented LY
uptake, whereas inhibition of the clathrin-dependent pathway
with chlorpromazine was ineffective (Figure 4I). Transmission
electron microscopy (TEM) confirmed induction of a massive
vacuolization in cells (7.5 mM, 6 hr; Figures 4J–4O). Clathrin-
coated endosomes are regular in size and are bounded by dou-
ble membrane. The numerous vacuoles observed in GCs were
large and of varying size, mostly empty and bounded by a single
membrane (Figures 4N and 4O), features that are consistent
with macropinosomes (Overmeyer et al., 2008). The lucent vac-
uoles were distinct from lysosomes, autolysosomes, and late
endosomes, which typically contain electron-dense organelle
remnants or degraded cytoplasmic components. Swollen endo-
plasmic reticulum and mitochondria and distorted bilayer struc-
tures of nuclear membrane was occasionally observed (Figures
4N, 4O, and S6). In cells on the verge of lysis, the vacuoles had
typically expanded to a point where much of the cytoplasmic
membrane was disrupted (Figure 4M). Macropinosomes
vary in size from0.5–5.0 mm, which is consistent with the range
of Vacquinol-1-induced vacuoles quantified by TEM (7.5 mM,
6 hr; Figure 4P). Macropinocytic vacuoles recruit the late endo-
somal and lysosomal marker LAMP1. Consistently, a marked
increase of LAMP1 immunofluorescence was observed that
occasionally also was associated with membrane protrusions
(7.5 mM, 6 hr; Figures 4Q–4T). These results provide evidence
for initiation of massive macropinocytosis by Vacquinol-1, lead-
ing to catastrophic vacuolization and resulting in a necrotic-like
cell death.
Requirement of MKK4 Activation for Vacquinol-1-
Induced Macropinocytosis
An unbiased short hairpin RNA (shRNA) screen was used to
identify pathways for Vacquinol-1-induced vacuolization. The
approach was based on the idea that depleting a key factor in
the pathway should render GCs refractive to Vacquinol-1-
induced death. A DECIPHER lentiviral shRNA library consisting
of 27,500 shRNAs covering 5,043 target genes (Human Module
1) were used to transduce U3013MG GCs. Surviving cells after
24 hr of Vacquinol-1 (14 mM; Figure 5A) displayed markedly
different cell appearance (Figures 5B and 5C). The resulting Vac-
quinol-1-resistant GCs displayed an IC50 of 14.3 ± 1.16 mM on
GC viability (Figure 5D), similar to fibroblasts (IC50 of 18.7 ±
0.06 mM). Sequencing of DNA prepared from the resistant GCs
revealed an enrichment ofMAP2K4 shRNA viruses (Figure S7A).
Fluorescence staining and western blot analyses of GCs for acti-
vating phosphorylation of MKK4 encoded by MAP2K4 revealed
a rapid and pronounced activation by Vacquinol-1 (7.5 mM) from
5min to 26 hr of stimulation (Figures 5E–5K). No effect on histone
H3K27 methylation was observed (Figure 5K). Abrogation of
MKK4 activity by two independent shRNAs led to marked in-
crease of the IC50 viability of Vacquinol-1-treated GCs (94%
knockdown of protein level, n = 3; Figures 5L, S7B, and S7C).
Phosphorylated MKK4 rapidly organized as punctate cyto-
plasmic staining in Vacquinol-1-treated cells (7.5 mM, 12 hr; Fig-
ures 5M and 5N). These results identify activation of MKK4 as aCell 157, 313–328, April 10, 2014 ª2014 Elsevier Inc. 317
Figure 3. A Rapid Induction of Membrane Ruffling and Vacuolization by Vacquinol-1
(A and B) Ca2+ flux in GCs.
(C and D) LC3-II immunoreactivity (Vacquinol-1, 7.5 mM).
(E and F) SEM analyses of GCs (7.5 mM Vacquinol-1 for 7 hr, red arrowheads point at membrane indentations).
(legend continued on next page)
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critical node in the signaling pathway executing Vacquinol-1-
induced death of GCs.
MKK4 was confirmed required for the process of Vacquinol-
1-induced macropinocytosis. Thus, following knockdown of
MAP2K4, GCs became refractory to Vacquinol-1-induced
vacuolization and LY incorporation (Figures 5O–5U), similar to
osteosarcoma cells (Figures 5S and 5T), showing that resistance
to death is associated with a defective formation of macropino-
cytic vacuoles induced by Vacquinol-1. Thus, the distinctive
feature of vulnerability to macropinocytosis and death in GCs
requires MKK4 activity.
Efficacy of Vacquinols Is Governed by Selective
Chemical Features
Acquisitionof structural analogs fromNCI/DTP (http://dtp.cancer.
gov), along with chemical synthesis (Extended Experimental Pro-
cedures; Data S1), was used for identification of potent deriva-
tives, as well as insight into the SAR of Vacquinol-1 (Figure 6).
Key chemical features critical for efficacy were identified by
measurements of IC50 in viability assay. Ab-hydroxyaminomoiety
in the 4 position of the quinoline core was invariably crucial.
In accordance, all analogs containing either the ketone or
carbamide in this position were inactive (Figure 6, compounds
2–3), as was the analog without this moiety (Figure 6, compound
5). Replacing piperidine with pyrrolidine (Figure 6, compound 6)
marginally attenuated activity, whereas pyridine (Figure 6, com-
pound 7) as an isostere of piperidine resulted in a complete loss
of potency. Piperidine N-methylation (Figure 6, compound 8)
gave a dramatic drop in effect, whereas methylation of the vicinal
alcohol was tolerated (Figure 6, compound 4). Surprisingly, three
of the four possible stereoisomers of Vacquinol-1 were roughly
equipotent, with one isomer slightly less active (data not shown).
The quinoline core and 2-(4-chlorophenyl) moiety were more
tolerant of variation, as the corresponding benzoquinoline
(Figure 6, compound 15) resulted in the hitherto most potent
compound identified in the Vacquinol series (IC50 = 0.39 mM).
Additional positions of the core scaffold were amenable to func-
tionalization with slight or no effect on activity (e.g., compound
13 and 14).
The 2-phenylquinoline core structure also appeared to be
crucial for activity, as the analogous 4-pyridinyl compounds
with (Figure 6, compound 20) or without (Figure 6, compound
19) the pendant 2-phenyl group were completely inactive. Simi-
larly, removal of the 2-(4-chloro)phenyl ring resulted in complete
abrogation of effect (Figure 6, compound 21). The in vitro effi-
cacy of evaluated compounds showed a high correlation to
in vivo effects in the zebrafish xenograft model (Figure 6).
In summary, these results show that modification of the b-hy-
droxypiperidine moiety or change of the quinoline scaffold of
Vacquinol-1 lead to dramatic shifts in potency, whereas substi-
tutions on the scaffold and pendant 2-phenyl group are toler-
ated. Modifications that are expected to only marginally affect
physicochemical properties—e.g., pKa or logP—gave large var-(G) Live imaging of GCs (15 mM Vacquinol-1). Images collected at times of major
(H) (H1 and H12) Live imaging with interference contrast optics of GCs (Vacquino
vacuole expanding in size). Scale bars, 50 mm (C), 5 mm (E), 20 mm (G), 20 mm (H
Abbreviations: s, seconds; min, minutes; SEM, scanning electron microscopy. Siations in activity, supporting the hypothesis that the compounds
exert their phenotypic response through binding to a specific
protein target (or targets). However, as all compoundswere eval-
uated and triaged in the primary GC viability assay, beyond bind-
ing affinity to putative pharmacological targets, pharmacokinetic
properties such as membrane permeability are likely contrib-
uting factors of compound efficacy in cells.
In Vitro Preclinical Profiling of Vacquinol-1
In vitro physicochemical testing of Vacquinol-1 (i.e., solubility,
pKa, and logP/D) indicates typical characteristics of a cationic
amphiphilic drug (eg., high basic pKa, high logP/D), albeit an
apparent high solubility in artificial cerebrospinal fluid (ACSF).
ADME profiling confirmed that Vacquinol-1 exhibits high
apparent membrane permeability (Papp) in Caco-2 cell mono-
layers. A slight efflux was detected, which was completely in-
hibitedby theGF120918 (Elacridar), an inhibitor ofP-glycoprotein
(Hyafil et al., 1993). Further, Vacquinol-1wasmetabolically stable
in human and mouse liver microsomes, as well as in freshly pre-
pared human hepatocytes. Thus, Vacquinol-1 is predicted to be
highly absorptive over biological membranes and resilient to
metabolism, which indicates high bioavailability (Table S3).
Attenuation of Tumor Growth In Vivo and Prolonging
Survival by Vacquinol-1
Based on these results, Vacquinol-1 appeared as a promising
candidate molecule for the treatment of glioblastoma. The ze-
brafish xenograft glioblastoma model was developed for quanti-
tative analyses of tumor development and infiltration in the host
brain (Figures S7D and S7E). Within 1 week after fluorescently
labeled U3013MG cells were injected, GCs rapidly expanded
and formed a tumor cell mass within the ventricle and started
to infiltrate the brain (Figures 7A and 7B). The developing tumors
stained for human nuclear antigen (Figure S7D). Quantification of
area, fluorescence level, and infiltration (distance from ventricle)
revealed beneficial effects of Vacquinol-1 on all parameters
(10 days, 15 mM in aquarium water; Figures 7C–7I). The ability
of Vacquinol-1 to attenuate tumor progression was next exam-
ined in a mouse model for human GBM. NOD/SCID mice
received intracranial injections of U3013MGCs, and the resulting
tumor was allowed to develop for 7 weeks. All mice presented
with large and highly vascularized tumors infiltrating the host
brain and often displayed massive areas of necrosis, overtly
observed during dissection of the brains (n = 5, Figure 7J1).
Histopathologic analysis revealed several features of GBM,
including pseudopalisading necrosis, mitotic cells, and exten-
sive microvascular proliferation (Louis et al., 2007) (Figures
7J1–7J3 and S7F). Tumors were highly immunoreactive for hu-
man Nestin (hNestin) and human GFAP (hGFAP). Vacquinol-1
(15 mM, 0.5 ml/hr) or vehicle (DMSO) were administered intra-
cranially into the site of original cell deposit 6 weeks after
engraftment. Despite the advanced stage of cancer at the time
of Vacquinol-1 administration, whole-brain morphology wasphenotypic changes.
l-1, 3.5 mM). Note increase in vacuole number and size (arrowhead points at a
1), and 10 mm (H2).
ee also Figure S4 and Movies S1, S2, and S3.
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Figure 4. GC Vulnerability to Macropinocytosis and Catastrophic Vacuolization Resulting in Cell Death
(A) Merge of optical interference contrast planes (Vacquinol-1 7.5 mM, arrowhead indicates vacuole).
(B–H) LY accumulation in GCs. Arrowhead in (F)–(H) points to a LY-containing vacuole.
(legend continued on next page)
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markedly normalized after 1 week treatment (Figures 7J1 and
7K). Tumors were invariantly smaller, and the area of necrosis
and hGFAP and hNestin immunoreactivity was significantly
reduced (Figures 7L–7O and S7G). Only tumor cells in Vacqui-
nol-1-treated mice displayed amassive LAMP1 staining (Figures
7P and 7Q). These results show that Vacquinol-1 activates
similar cellular responses in vivo as in vitro, that activation of
this pathway is selective for GBM as no staining was observed
in the host brain, and that it has the capacity when administered
into the brain to attenuate tumor growth.
Encouraged by these results, we investigated the bioavail-
ability of Vacquinol-1 in vivo by oral (p.o.), intravenous (i.v.),
and intraperitoneal administration. The i.v. plasma kinetics
lacked a clear distribution phase, which indicates a rapid tissue
distribution (apparent distribution kinetic phase visible in brain
i.v.) after administration and a relatively large calculated volume
of distribution, as predicted by in vitro ADME data. The pharma-
cokinetics of Vacquinol-1 showed a maximal plasma exposure
of 3,279 ng/ml and good penetrance into the brain with exposure
of 1,860 ng/ml following a single oral dose of 20 mg/kg (Figures
S7H, S7J, and S7K). As predicted from the in vitro evaluation of
metabolic stability, Vacquinol-1 was highly stable in vivo with
very low systemic plasma clearance (t1/2 = 52 hr in plasma) (Fig-
ure S7H). Based on these results, the ability of oral Vacquinol-1
administration (20 mg/kg) once daily for 5 days to affect disease
progression was examined by MRI measurements of tumor vol-
ume in the above-described xenograft GBM model. Treatment
started at 6 weeks after engraftment of U3013M GCs, and ani-
mals were analyzed at week 8. During dissection, brains from
vehicle treated mice displayed hemorrhage, areas of necrosis,
and increased brain weight (n = 7), whereas brains from Vacqui-
nol-1-treated mice (n = 13) showed a normal brain morphology
and had a normalized brain weight (Figures 7S and S7I). Analysis
by MRI revealed large tumors in all vehicle-treated mice with
significantly smaller (four animals) or complete absence (nine
animals) of detectable tumors in Vacquinol-1-receiving mice
(Figures 7R, 7T, and S7L). These results urged us to examine
whether survival can be prolonged by Vacquinol-1. Mice
receiving oral administration of Vacquinol-1 2 weeks after
engraftment of U3013M GCs (20 mg/kg once daily for 5 days)
displayed a temporary 10.8% ± 8.1% loss of body weight but
regained weight to controls 1–2 weeks after end of treatment.
Vacquinol-1 significantly enhanced survival as compared to
vehicle-treated mice. Vehicle-treated animals (n = 8) showed a
median survival of 31.5 days, whereas only two of the eight Vac-
quinol-1-treated mice died during the 80 days of the experiment
(Figure 7U, p = 0.0004 Mantel-Cox test). Hence, we conclude
that oral administration of Vacquinol-1 substantially impairs
disease progression and prolongs survival.(I) Percent of LY-positive cells in the presence or absence of indicated inhibitors
(J–O) TEM images of GCs. Note that (K), (L), and (M) represent cells at different
points at nuclear membrane, blue arrow points at swollen mitochondria, asterisk i
vacuoles with some electron-dense material.
(P) Quantification of number and size of vacuoles per cell.
(Q–T) Immunostaining of GC for LAMP-1. Scale bars, 20 mm (A), 50 mm (B), 10 m
Abbreviations: BafA1, Bafilomycin A; Chlorp, Chlorpromazine; CytoD, cytochalsin
Vacq, Vacquinol-1. Mean ± SD. See also Figure S6.DISCUSSION
We have undertaken a functional screen of GCs based on
the assumption that the accumulation of genetic alterations
affecting intracellular signaling pathways underlying tumorigen-
esis also can result in gained cellular vulnerability not necessarily
involved in the cancerous process. One biological process was
identified in this screen that resulted in a robust loss of viability
and increased display of cytotoxicity in GCs. The effect occurs
independently of engaging apoptotic or autophagic pathways
or overtly compromising mitochondria. Instead, cytotoxicity
was found to be conferred by a mechanism involving induction
of massive macropinocytosis, resulting in catastrophic vacuoli-
zation and death. This effect was found only in GCs, as mESCs,
fibroblasts, mouse astrocytes, neurons, and several other types
of cancer cells did not respond similarly to Vacquinol-1.
The biological process initiated by Vacquinol-1 involves
massive membrane ruffling and blebbing within seconds after
stimuli onset, cell rounding, followed by vacuole formation,
which, in a time and concentration-dependent manner, in-
creases in number and size and eventually leads to a disruption
of cell membrane integrity and cell death. Themolecular target of
Vacquinol-1 and/or enrichment of downstream signaling path-
ways appear to confer a specificity of vacuolization toGBMcells.
The massive buildup of vacuoles shows that any clearance of
vacuoles by recycling or fusion with other endosomal compart-
ments is insufficient. These characteristics are shared with
macropinocytic vacuoles observed by forced expression of
constitutively activated Ras (Bhanot et al., 2010; Overmeyer
et al., 2008). Because TMRE staining of mitochondria was not
affected, indicating that membrane potential is unperturbed,
we believe that the energy-consuming processes of massive
membrane ruffling, retraction of blebs, and acidification of vacu-
oles contributes to the cellular depletion of ATP and is part of the
high cytotoxicity of Vacquinol-1. Blebs are typically associated
with macropinocytosis and are caused by a loss of the tight con-
tact between the plasma membrane and the underlying layer of
actin and myosin cortex, which holds the membrane under ten-
sion. Thus, when the plasma membrane separates from the cor-
tex, the cytoplasmic pressure leads to formation of membrane
blebs, which lacks the actin cytoskeleton (Charras and Paluch,
2008). The retraction of blebs is associated with actin reassem-
bly and reattachment of the membrane to the actin cortex. Dur-
ing the final stage of Vacquinol-1-induced cell toxicity, we often
observed by live imaging an initial cytoplasmic membrane
contraction followed by a very fast expansion of the membrane,
resulting in lysis of the cytoplasmic membrane. This finding is
consistent with actin reassembly followed by a complete dis-
solving actin cortex attachment and thereby release of the.
stages of the cell death process. Arrowheads points at vacuoles, white arrow
ndicates swollen endoplasmic reticulum, and red arrow points at relatively rare
m (D), 1 mm (J), 200 nm (N), 50 mm (Q), and 10 mm (R).
D; Dyn, Dynasore; LY, lucifer yellow; TEM, transmission electron microscopy;
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tension exerted by the hydrostatic pressure of the cytoplasmic
membrane, leading to its fast expansion and lysis. This process
is expected to be affected both by an increased membrane ten-
sion due to the diminishing content of cytoplasmic membrane
caused by the vacuolization and by depletion of ATP that is
required for actin reassembly.
Glioblastomas are highly aggressive and infiltrative and
frequently recur after treatment. The main therapy involves radi-
ation and chemotherapy with temozolomide (TMZ) (Stupp et al.,
2005) that act by reducing cell viability causing apoptosis and
senescence (Gu¨nther et al., 2003). Precisely how recurrence oc-
curs is unknown but may involve clonal expansion of cells with
accumulated mutations, rendering cells refractive to current
treatment strategies (Zhang et al., 2010). Cellular heterogeneity
of glioblastoma may also contribute to tumor recurrence, as
the endogenous glioma cells with properties of cancer stem cells
is a quiescent population (Alcantara Llaguno et al., 2009; Singh
et al., 2004). TMZ and radiotherapy act primarily on rapidly
dividing cells and may fail in due course because they cannot
kill the subpopulation of relatively quiescent tumor-initiating cells
(Bao et al., 2006; Chen et al., 2012a). The molecular action of
Vacquinol-1 onmacropinocytosis is expected to be independent
of cell proliferation and therefore should target relatively quies-
cent stem-like tumor-initiating cells with similar efficiency as
rapidly dividing cells. As it targets a new and independent
pathway, Vacquinols are also expected to be efficient for drug-
resistant cancer. Although Vacquinols could be efficient as
monotherapy, the rapid loss of ATP would be expected also to
potentiate cytotoxicity in combination therapy approaches.
The in vitro preclinical profiling and in vivo pharmacokinetics of
Vacquinol-1 indicate promising CNS drug properties such that it
is highly stable in vitro/in vivo with low systemic clearance and
high passive permeability and that it displays good penetrance
into the brain. Mice were found to be highly tolerant to Vacqui-
nol-1, as administration with 20 mg/kg p.o. for 5 days did not
result in a sustained weight loss, showing that the potential
buildup of high plasma concentrations at steady state does not
compromise survival. These results suggest that an adequate
concentration for cytotoxicity of glioblastoma without severe un-
wanted effects to transpire possibly can be achieved in vivo
following administration.
Macropinocytosis is induced by the activation of tyrosine
kinase receptors, integrins, or other cell-surface receptors,
which causes a general elevation of actin polymerization at the
cell surface, resulting in membrane ruffles that close at the distalFigure 5. Dependence on MKK4 for Macropinocytosis and Catastroph
(A) Schematic illustration of the RNAi screen.
(B and C) Morphology of control and Vacquinol-1-resistant GCs.
(D) Viability (ATP) dose response of Vacquinol-1-resistant GCs.
(E–J) Immunocytochemical staining for phospho-MKK4.
(K) Western blot analysis for phospho-MKK4, H3K27me3, and H3 as loading con
(L) Dose response of viability (ATP) of MAP2K4 shRNA-transduced GCs exposed
MKK4 shRNA-transduced cells.
(M and N) Immunocytochemical staining of GC for phospho-MKK4.
(O–T) LY accumulation in resistant cells, scrambled control, and MAP2K4 shRNA
(U) Quantification of percent LY-positive cells from the experiments shown in (O
Abbreviations: SCR or CTR, scrambled shRNA control; GC, glioblastoma cells; L
osteosarcoma cells. Mean ± SD; t test, *p < 0.05 and **p < 0.01. See also Figuremargins to engulf extracellular fluid (Haigler et al., 1979; Mercer
and Helenius, 2012; Swanson, 2008). Thus, when ruffles curve
into open, crater-like cups at the cell surface membrane, ruffle
closure is followed by cup closure, separating the macropino-
some from the plasma membrane. The massive cell ruffles
observed after Vacquinol-1 addition, followed by cell membrane
invaginations, could therefore be closely linked to the formation
of macropinosomes.
The MAPKK, MKK4 encoded byMAP2K4, was found as a key
signaling element for Vacquinol-1-induced macropinocytosis.
MKK4 belongs to the stress/GPCR agonists/cytokine/growth
factor-activated pathway, which previously is associated with
inflammation, apoptosis, growth, and differentiation processes
(Morrison, 2012), but we cannot find any previous knowledge
on its participation in vacuolization. MAP2K4 loss of function is
observed at 5% across a wide spectrum of cancers, including
those of the breast, lung, pancreas, bile duct, prostate, and
ovary, but its role appears complex, and both tumor suppressor
and pro-oncogenic activities are consistent with its engagement
in multiple cellular processes (Whitmarsh and Davis, 2007).
The mechanism of MKK4 activation and its requirement for
macropinocytosis and vacuolization are not fully understood
but could be engaged downstream of Ras-activated Rac1.
MAP2K4 has not been shown to be mutated in GBM, but nearly
all tumors (88%) display alterations in receptor tyrosine kinase/
Ras signaling. Constitutively active Ras, if ectopically expressed,
can drivemacropinocytosis in a glioblastoma cell line (Kaul et al.,
2007; Overmeyer et al., 2008). It is possible that an elevated Ras
signaling participates inMKK4 activation in glioblastoma and un-
derlies the vulnerability of GCs to Vacquinol-1-induced vacuoli-
zation. However, GCs displayed a low constitutive uptake of
LY in the absence of Vacquinol-1, indicating that endogenous
Ras activity in these tumor cells is insufficient by itself for initi-
ating high levels of macropinocytic activity. The critical role of
MKK4 for macropinocytosis warrants studies to determine
whether it is essential for induction of macropinocytosis in
all its forms, including physiological processes, for instance, dur-
ing uptake of bacteria, apoptotic bodies, necrotic cells, and
viruses.
Vacquinol-1 (NSC13316) stems from a class of b-aminohy-
droxyquinolines originally developed for antimalarial application
(Brown and Jacobs, 1946; Pinder andBurger, 1968; Rapport and
Senear, 1946). A close analog to Vacquinol-1, NSC23925, has
recently been reported to reverse P-glycoprotein-mediated
efflux of several cancer drugs in multidrug-resistant cancer cellic Vacuolization in GCs
trol.
to Vacquinol-1 and western blot analyses of the knockdown efficiency of the
-transduced GCs and osteosarcoma cells.
)–(T). Scale bars, 100 mm (B and E), 50 mm (F), and 10 mm (M).
Y, lucifer yellow; R, resistant GCs from shRNA screen; Vacq, Vacquinol-1; OS,
S7.
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Figure 6. Structure-Activity Relationship of
Vacquinols
Generic structure of Vacquinol-1 with modified
positions represented by X, Y, R1, and R2.
Representative compounds (compound ID) with
various combinations of structural modification at
site X, Y, R1, and R2 and their impact on its activity
measured by dose response of viability (ATP) of
GCs determined IC50 (24 hr) indicated, followed
by some representative compound effects in the
zebrafish xenograft model. Number at right bottom
corner of the zebrafish xenograft panels (xeno-
transplanted GCs, red) indicates the compound
number from the left side of the table. Scale bar,
100 mM. Abbreviations: e, eye; (a) IC50 values of
quadruplicate data calculated from a logarithmic
11 point dose response; (b) Vacquinol-1; (c) Ymin
not reached, indicating that the highest concen-
tration evaluated in dose response did not reach
full inhibition of viability relative to positive control,
resulting in incomplete curves.lines (Duan et al., 2009, 2012), although no direct cytotoxic effect
of the compound itself was evident. In GCs, however, NSC23925
displayed an IC50 of 7.59 mM (Figure 6), only slightly less potent
than Vacquinol-1. Compounds from the same class were
recently described also as inhibitors of bacterial biofilm forma-
tion (Leo´n et al., 2013) and as inhibitors of SHIP1/2 in multiple
myeloma cell lines (Fuhler et al., 2012).
Vacquinol-induced cell death does not appear to confer an un-
specific cytotoxicity, as other cell types showmarginal or no loss
of viability in the presence of Vacquinol-1 at comparitive concen-324 Cell 157, 313–328, April 10, 2014 ª2014 Elsevier Inc.trations. Accumulation of phase-lucent
vacuoles is consistently observed in all
active members of the Vacquinol family
of compounds (data not shown) at 10- to
100-fold lower concentrations than the
corresponding IC50 of GC viability. No vac-
uoles could be observed in alternative cell
lines, at any concentration, regardless of
the level of cytotoxicity observed in these
cells. We believe that induction of this
phenotype is a critical contributor to in vivo
efficacy.
The structure-activity relationship (SAR)
of Vacquinols reveals an exquisite depen-
dence on the piperidin-2-ylmethanol moi-
ety in the 4 position of the quinoline. Few
modifications were tolerated in this region,
although variability could be introduced in
other positions of the quinoline and/or the
pendant phenyl group in the 2 position
while maintaining effect. In contrast to the
reported stereochemical superiority of a
single isomer of NSC23925 in reversing
Pgp-mediated drug resistance in SKOV-3
cell lines (Duan et al., 2012), three of the
four possible isomers of Vacquinol-1were roughly equipotent (data not shown). Thus, we did not pur-
sue a stereospecific synthesis.
The long in vivo half-life of Vacquinol-1, in concert with its
quinine-like lipophilic amine structure, suggested that the com-
pound may be lysosomotropic in character, similar to the auto-
phagy inhibitor chloroquine. Chloroquine has been described
as toxic for glioblastoma cell lines through the induction of auto-
phagic vacuole accumulation (Geng et al., 2010), a sensitizer of
radiation-induced cell death of GCs (Firat et al., 2012) and as
an adjuvant of conventional therapies of GBM (Sotelo et al.,
Figure 7. In Vivo Effects of Vacquinol-1 Treatment in Animal Models of GBM
(A) (A1 and A2) GCs (red) transplanted into islet1:GFP transgenic zebrafish brain imaged at 48 hours postfertilization (hpf) (A1) or after 1 week (A2). White arrows
indicate transplanted cells.
(B) (B1 and B2) Three-week-old xenografted zebrafish larvae (red GCs indicated by arrow).
(legend continued on next page)
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2006). However, chloroquine showed no intrinsic activity on GCs
in our hands (Figure 6) and induced no vacuole accumulation. In
addition, electron microscopy reveals that vacuoles induced by
Vacquinol-1 are single-membrane bound, thus not autophago-
somal in origin.
In addition to the long in vivo pharmacokinetic profile and oral
bioavailability, Vacquinol-1 exhibits favorable overall preclinical
characteristics. Although in vivo tolerance appears high and
could be adequate for clinical utility, one possible obstacle for
further clinical development of Vacquinol-1 is the effective ther-
apeutic window in vitro, as unrelated toxicity appears at around
15 mM. The identification of compounds with higher selective
activity toward GCs may improve this window.
By taking an unbiased strategy, we have identified a vulnera-
bility to a macropinocytosis-associated catastrophic vacuoliza-
tion as a selective feature of GBM and provide evidence for its
targeted induction by a small molecule. We provide mechanistic
and molecular insights for the cellular processes and signaling
pathways involved and describe the structure-activity relation-
ship of Vacquinol-1 for maintaining activity. Furthermore, our re-
sults provide evidence for an efficient in vivo induction of the
same signaling pathway in animal models of GBM and show
that tumor development can markedly be attenuated without
apparent effects on host brain tissue. Thus, we have identified
an acquired cellular property in GBM that can be readily targeted
with small molecules displaying suitable properties for clinical
development that rapidly and selectively depletes glioblastoma
cells, attenuates disease progression, and prolongs survival in
a GBM animal model.
EXPERIMENTAL PROCEDURES
GC Isolation and Screen
GBM grade IV biopsies were obtained and cultured according to Pollard et al.
(2009). The NCI Diversity Set II small-molecule library was screened on GC
lines U3013 and U3047 and was compared with mESCs and fibroblast cells
to identify compounds affecting only GCs. The identified compounds were
then exposed to a panel of other GC lines (U3013, U3047, U3024, U3031,
U3037, U3086, U3054, and U3065), and the effect was documented.
Multiparametric Assays
Multiparametric assays of the 63 and 17 compounds were conducted in 384-
well microtiter plates seeded with 10,000 cells. Cell viability, cytotoxicity, and(C–F) Whole-mount images (C and D) and sections (E and F) of GC (red) tran
Vacquinol-1).
(G–I) Quantification of (C)–(F).
(J) (J1–J3) GC xenotransplanted mouse brain treated with DMSO. Hematoxylin- a
and J3); note apopototic figures (white arrow in J2) and mitoses (white arrow in J
(K) GC xenotransplanted brain treated intracranially with Vacquinol-1.
(L–O) Immunohistochemical staining with anti-human GFAP antibody on GC xen
positive (N) and necrotic area (O).
(P and Q) Immunohistochemical detection of LAMP1-1 (red) in GC xenotransplan
(R) MRI of GC transplanted mouse brains following treatment either with DMSO o
from a different mouse.
(S) Measurement of total brain weight of wild-type animal or GC transplanted mi
(T) Measurement of tumor volume in brains imaged by MRI following treatment w
(U) Kaplan-Meier survival curve of mice transplanted with GCs. A 5 day oral treat
and is indicated by a black horizontal bar on the x axis. A significance or p = 0.0
Scale bars: zebrafish panels, 100 mm, 2.5 mm (L1), 5 mm (L2), 0.1 mm (L3), 2 mm
***p < 0.001. See also Figure S7.
326 Cell 157, 313–328, April 10, 2014 ª2014 Elsevier Inc.apoptosis were measured using CellTiter-Glo Luminescent Cell Viability
Assay, CytoTox-Glo Cytotoxicity Assay, and Caspase-Glo 9 Assay (Promega)
according to the manufacturer’s instructions. Mixed culture assay was per-
formed with 1,000 labeled cells in hanging drop cultures. The dilution and
recovery assay was performed by 2 day compound treatment followed by
analysis after an additional 2 days without compound on GCs. Cell-cycle
profiling was performed by propidium iodine flow cytometry and apoptosis
by quantitative flow cytometry. Ratiometric calcium imaging and ADME ana-
lyses were performed according to previously published procedures. IC50
was determined using Cell Viability assay.
Live Imaging and In Vivo Tests
Live imaging was performed on an Operetta High Content imaging system
(PerkinElmer). Toxicity on embryos and cardiac toxicity was assessed in
Zebrafish. For tumor development, zebrafish or NOD-SCIDmice were injected
with 3,000 or 100, 000 cells, respectively.
RNAi Screen
We used a DECIPHER lentiviral shRNA library consisting of Human Module 1,
which includes a targeting of signaling pathways. In total 27,500 shRNAs
targeting 5,043 genes were used. Viruses enriched in surviving cells after Vac-
quinol exposure (14 mM) were identified by deep sequencing.
Chemical Synthesis
Chemical syntheses were performed at CBCS, Karolinska Institutet, Stock-
holm, Sweden and SAI Life Sciences, Hyderabad, India. All final compounds
were purified to R95% purity according to UV detection (305 ± 90 nm) and
identity verified by mass spectrometry (MS) and NMR spectra before evalu-
ated in biological assays. A full description of chemistry and associated ana-
lyses can be found in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one data file, three tables,
and three movies and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2014.02.021.
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